Locations:
Search IconSearch
April 9, 2019/Neurosciences

New PRESTO Board Aims to Boost Role of Mobile Treatment in Stroke Management

Board member Shazam Hussain, MD, outlines the group’s goals

19-NEU-317-mobile-stroke-650×450

The international PRE-hospital Stroke Treatment Organization (PRESTO) is preparing to bolster its support of mobile stroke units with the formation of its first board of directors, and Cleveland Clinic stroke neurologist M. Shazam Hussain, MD, is among them.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Dr. Hussain, Director of Cleveland Clinic’s Cerebrovascular Center, was elected by the PRESTO membership in March to one of four seats on the board representing the Americas. The board of directors has a total of 13 seats — nine representing global regions that have embraced mobile stroke treatment and four representing supporting specialties, such as nursing and radiography.

“PRESTO has reached the point where we needed a more formalized structure, which is why the board has been created,” says Dr. Hussain. “It will be helpful to advancing the organization as PRESTO continues to grow and mature.”

Dr. Hussain has witnessed that growth from the start, as Cleveland Clinic was among a handful of centers that founded the international consortium. “The first two mobile stroke units were launched in Germany, and the next two were in the United States — at the University of Texas in Houston and at Cleveland Clinic,” he explains. “These four programs, along with a few other centers that had interest in mobile stroke treatment at the time, began to meet at the International Stroke Conference in the U.S. and at the European Stroke Organization Conference. At those meetings we gradually came up with the idea of starting a more organized group to support and advise on prehospital treatment, specifically mobile stroke treatment units.”

The result was the formation of PRESTO around the time of a May 2016 mobile stroke summit hosted by Cleveland Clinic. The organization adopted a mission of improving outcomes of patients with acute stroke worldwide by supporting research and advocacy for prehospital treatment in mobile stroke units. Its central objectives are to be a platform to enhance collaborative research and to support the proliferation of mobile stroke units through professional communication, public education and advocacy to government and industry. The rationale for PRESTO and its organizational structure were detailed in a 2017 white paper published by its founding leaders in the International Journal of Stroke (2017;12:932-940).

Advertisement

“PRESTO does everything from advocating to governments for appropriate reimbursement of mobile stroke treatment to helping new centers build their own mobile stroke programs to supporting research and educational initiatives,” Dr. Hussain notes. “We are seen as the experts on mobile stroke treatment, and our new board will help us make that more and more the case.”

The next PRESTO meeting will be at the 2019 European Stroke Organization Conference in Milan in May.

Advertisement

Related Articles

Portrait of Dr. Oguh
Ataxia: A Symptom That Points to the Need for a Deeper Dive (Podcast)

Multidisciplinary care can be key to managing challenging condition

pathology slice of human spinal cord
Unmasking Spinal Cord Pathology in MS: 7T MRI Reveals Neurodegeneration Beyond Demyelination

Novel insights from a postmortem study combining imaging, pathology and clinical perspectives

Man with leg prosthetic tying shoe
April 29, 2025/Neurosciences
QUEST Study: Self-Administered High-Frequency Nerve Block Effective for Postamputation Pain

Relieves discomfort, reduces opioid dependency and improves quality of life

Dr. Robert Fox against a decorative background with a podcast icon overlay
April 16, 2025/Neurosciences/Podcast
Emerging Therapeutic Options in Progressive Multiple Sclerosis (Podcast)

Long-awaited efficacy against disability progression appears to be at hand

medication vials, syringes, tablets and capsules on a tabletop
Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

illustration of brain plus chemical diagram of tavapadon
April 11, 2025/Neurosciences/Research
TEMPO: Tavapadon Shows Promise as Both First and Adjunct Therapy in Parkinson’s

Dopamine agonist performs in patients with early stage and advanced disease

Illustration of head and brain to depict migraine pain
Transnasal Evaporative Cooling Effective for Acute Treatment of Migraine Pain

A flow of dehumidified room air delivered via at-home device modulates sphenopalatine ganglion

hand pointing at brain scans on a computer monitoring
Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

Ad